Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

Please provide your email address to receive an email when new articles are posted on . The photopneumatic device improved acne in 66.7% of patients in this 7-week trial. Improvements were seen across ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. In a clinical trial, ...

According to the American Academy of Dermatology, acne affects up to 50 million people in the United States every year. Though it’s the most common skin condition in the U.S., determining the best ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...

Hispanic and Black girls with PCOS-related acne receive less prescriptions for acne treatment when compared with White girls.